PM
DNTH icon

Prosight Management’s Dianthus Therapeutics DNTH Stock Holding History

Prosight Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,853
Closed -$985K – 43
2020
Q4 		$985K Sell
7,853
-7,413
-49% -$840K 0.46% 36
2020
Q3 		$1.66M Buy
15,266
+4,730
+45% +$560K 0.79% 33
2020
Q2 		$1.27M Buy
+10,536
New +$1.48M 0.54% 39

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Prosight Management's DNTH Position: Q1 2021 in Review

Prosight Management sold out of Dianthus Therapeutics (DNTH) in Q1 2021, closing a stake of 7,853 shares — an estimated $985K sold.

Prosight Management first reported a position in DNTH in Q2 2020 and held it in 3 quarters. The position peaked at $1.66M in Q3 2020. 90 funds tracked by Wall St. Rank hold DNTH as of Q1 2021.

  • Prosight Management reported no remaining Dianthus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Prosight Management sold 7,853 Dianthus Therapeutics shares in Q1 2021, an estimated $985K.
  • Prosight Management first reported a position in Dianthus Therapeutics in Q2 2020 and held it in 3 quarters.
  • Prosight Management's Dianthus Therapeutics position peaked at $1.66M in Q3 2020.
  • 90 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2021.

Based on Prosight Management's 13F filing for Q1 2021, filed 14 May 2021.